Publication:
Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries

Simple item page
dc.contributor.authorMedel-Jara, Patricio
dc.contributor.authorReyes Placencia, Diego
dc.contributor.authorFuentes-López, Eduardo
dc.contributor.authorCorsi, Oscar
dc.contributor.authorLatorre, Gonzalo
dc.contributor.authorAntón, Rosario
dc.contributor.authorJiménez, Elena
dc.contributor.authorMiralles-Marco, Ana
dc.contributor.authorCaballero, Carmelo
dc.contributor.authorBoggino, Hugo
dc.contributor.authorCantero, Daniel
dc.contributor.authorBarros, Rita
dc.contributor.authorSantos-Antunes, João
dc.contributor.authorDíez, Marc
dc.contributor.authorQuiñones, Luis A.
dc.contributor.authorRiquelme, Erick
dc.contributor.authorRollan, Antonio
dc.contributor.authorCerpa, Leslie C.
dc.contributor.authorValdés, Ivania
dc.contributor.authorNyssen, Olga P.
dc.contributor.authorMoreira, Leticia
dc.contributor.authorGisbert, Javier P.
dc.contributor.authorCamargo, M. Constanza
dc.contributor.authorOrtiz-Olvera, Nayeli
dc.contributor.authorLeon‐Takahashi, Alberto, M.
dc.contributor.authorRuiz-Garcia, Erika
dc.contributor.authorFernández-Figueroa, Edith A.
dc.contributor.authorGarrido, Marcelo
dc.contributor.authorOwen, Gareth I.
dc.contributor.authorCervantes, Andrés
dc.contributor.authorFleita, Tania
dc.contributor.authorRiquelme, Arnoldo
dc.date.accessioned2025-01-21T14:05:04Z
dc.date.available2025-01-21T14:05:04Z
dc.date.issued2024
dc.description.abstractIntroduction: Gastric cancer (GC) is one of the most lethal malignancies worldwide.Helicobacter pylori is the primary cause of GC; therefore, its eradication reduces therisk of developing this neoplasia. There is extensive evidence regarding quadrupletherapy with relevance to the European population. However, in Latin America, dataare scarce. Furthermore, there is limited information about the eradication ratesachieved by antibiotic schemes in European and Latin American populations.Objective: To compare the effectiveness of standard triple therapy (STT), quadrupleconcomitant therapy (QCT), and bismuth quadruple therapy (QBT) in six centers inEurope and Latin America.Methods: A retrospective study was carried out based on the LEGACy registry from2017 to 2022. Data from adult patients recruited in Portugal, Spain, Chile, Mexico,and Paraguay with confirmed H. pylori infection who received eradication therapyand confirmatory tests at least 1 month apart were included. Treatment success by each scheme was compared using a mixed multilevel Poisson regression, adjustingfor patient sex and age, together with country‐specific variables, including preva-lence of H. pylori antibiotic resistance (clarithromycin, metronidazole, and amoxi-cillin), and CYP2C19 polymorphisms.Results: 772 patients were incorporated (64.64% females; mean age of 52.93 years).The total H. pylori eradication rates were 75.20% (255/339) with STT, 88.70% (159/178) with QCT, and 91.30% (191/209) with QBT. Both quadruple therapies (QCT‐QBT) showed significantly higher eradication rates compared with STT, with anadjusted incidence risk ratio (IRR) of 1.25 (p: <0.05); and 1.24 (p: <0.05), respectively.The antibiotic‐resistance prevalence by country, but not the prevalence of CYP2C19polymorphism, showed a statistically significant impact on eradication success.Conclusions: Both QCT and QBT are superior to STT for H. pylori eradication whenadjusted for country‐specific antibiotic resistance and CYP2C19 polymorphism in asample of individuals residing in five countries within two continents.
dc.description.versionVersión publicada
dc.format.extent10 p.
dc.identifier.citationMedel-Jara P, Reyes Placencia D, Fuentes-López E, Corsi O, Latorre G, Antón R, Jiménez E, Miralles-Marco A, Caballero C, Boggino H, Cantero D, Barros R, Santos-Antunes J, Díez M, Quiñones LA, Riquelme E, Rollán A, Cerpa LC, Valdés I, Nyssen OP, Moreira L, Gisbert JP, Camargo MC, Ortiz-Olvera N, Leon-Takahashi AM, Ruiz-Garcia E, Fernández-Figueroa EA, Garrido M, Owen GI, Cervantes A, Fleitas T, Riquelme A. Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries. United European Gastroenterol J. 2024 Nov;12(9):1190-1199. doi: 10.1002/ueg2.12605
dc.identifier.doihttps://doi.org/10.1002/ueg2.12605
dc.identifier.urihttps://hdl.handle.net/11447/9683
dc.language.isoen
dc.subjectCombination drug therapies
dc.subjectGastric cancer
dc.subjectHelicobacter pylori
dc.subjectQuadruple therapy
dc.subjectStandardtriple therapy
dc.titleQuadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceUnited European Gastroenterology J .
dspace.entity.typePublication
relation.isAuthorOfPublicationac544e8b-a61f-4da5-b888-9de5caef44b4
relation.isAuthorOfPublication.latestForDiscoveryac544e8b-a61f-4da5-b888-9de5caef44b4

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
UEG Journal - 2024 - Medel‐Jara - Quadruple therapies show a higher eradication rate compared to standard triple therapy.pdf
Size:
423.91 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services